• Thumbnail for Omalizumab
    Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps...
    47 KB (4,925 words) - 22:57, 25 October 2024
  • in allergic reactions. The efficacy of omalizumab may vary among patients. To identify responders to omalizumab, the level of several biomarkers can be...
    28 KB (3,050 words) - 12:24, 6 August 2024
  • Thumbnail for Hypersensitivity
    control. Experimentally, a low dose of methotrexate or cyclosporin and omalizumab (a monoclonal anti-IgE antibody) has been used. Treatment of autoimmune...
    21 KB (1,860 words) - 04:32, 30 October 2024
  • Thumbnail for Autoimmune urticaria
    includes the use of antihistamines, corticosteroids, monoclonal antibodies (omalizumab), and in some cases, immunosuppressive drugs. Despite ongoing research...
    35 KB (3,673 words) - 06:34, 15 January 2024
  • Thumbnail for Hives
    long term antihistamine therapy is indicated. Immunosuppressants such as omalizumab or cyclosporin may also be used. About 20% of people are affected at some...
    50 KB (5,769 words) - 14:49, 25 October 2024
  • Thumbnail for Immunoglobulin E
    phase I to IV clinical trials of omalizumab in various indications, concluded that a causal relationship between omalizumab therapy and malignancy is unlikely...
    28 KB (3,269 words) - 04:10, 4 November 2024
  • Thumbnail for Chronic spontaneous urticaria
    off-label therapy with cyclosporine A or montelukast or add-on therapy with omalizumab, which is an approved treatment option for CSU. Angioedema, excruciatingly...
    47 KB (4,686 words) - 01:22, 2 November 2024
  • Thumbnail for Monoclonal antibody
    cells and thereby help prevent acute rejection of kidney transplants. Omalizumab inhibits human immunoglobulin E (IgE) and is useful in treating moderate-to-severe...
    48 KB (4,964 words) - 04:26, 20 October 2024
  • Thumbnail for Food allergy
    have generally been used to treat peanut and environmental allergies. Omalizumab, an injectable asthma treatment drug sold under the brand name Xolair...
    112 KB (12,197 words) - 18:12, 24 July 2024
  • Thumbnail for Cholinergic urticaria
    CU is rather limited in most cases. Treatment(s) with mixed success: omalizumab (anti-IgE therapy), danazol (synthetic androgen), propranolol (beta blocker)...
    17 KB (1,707 words) - 05:15, 6 July 2024
  • Thumbnail for Enteritis
    avoid food allergies, azathioprine and antibodies, including mepolizumab, omalizumab, infliximab, and adalimumab. The word enteritis (/ˌɛntəˈraɪtɪs/) uses...
    19 KB (1,905 words) - 04:24, 18 October 2024
  • Thumbnail for Asthma
    approaches to reducing autumn exacerbations, but while costly, seasonal omalizumab treatment from four to six weeks before school return may reduce autumn...
    167 KB (18,029 words) - 17:59, 27 October 2024
  • Thumbnail for Roche
    marboxil), for influenza A and B (both treatment and prevention). Xolair (omalizumab), for asthma, chronic idiopathic urticaria (CIU), and nasal polyps. Zelboraf...
    57 KB (5,195 words) - 10:21, 4 November 2024
  • have dangerous reactions to these drugs Monoclonal antibodies, such as omalizumab Corticosteroids The prognosis of MCAS is uncertain. The condition was...
    24 KB (2,442 words) - 18:52, 6 November 2024
  • as of December 2021. Subcutaneous injection of the anti-IgE antibody omalizumab is being studied as a method of preventing recurrence, but it is not yet...
    58 KB (6,223 words) - 04:36, 29 October 2024
  • International Nonproprietary Names of humanized antibodies end in -zumab, as in omalizumab (see Nomenclature of monoclonal antibodies). Humanized antibodies are...
    14 KB (1,787 words) - 23:05, 9 January 2024
  • Thumbnail for Allergen immunotherapy
    to OIT to reduce immune response. In 1 trial, the monoclonal antibody omalizumab was combined with high-dose milk oral immunotherapy and saw positive results...
    31 KB (3,504 words) - 18:39, 3 July 2024
  • Thumbnail for Cold urticaria
    Twinject) for use in the event of a serious reaction. Studies have found that omalizumab (Xolair) may be an effective and safe treatment for cold urticaria in...
    23 KB (2,552 words) - 05:23, 2 November 2024
  • Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. (March 2017). "Omalizumab facilitates rapid oral desensitization for peanut allergy". The Journal...
    59 KB (6,137 words) - 22:03, 11 October 2024
  • Thumbnail for Rhinovirus
    has been shown to reduce viral load and pro-inflammatory IL-1β in mice. Omalizumab, which was developed for treatment of severe allergic asthma, has shown...
    30 KB (3,474 words) - 01:01, 4 November 2024
  • Thumbnail for Novartis
    Prevention of bone fractures in cancer patients 1,288 2012 −13% Xolair (omalizumab) Moderate-to-severe asthma not controlled by inhaled steroids Chronic...
    144 KB (12,146 words) - 09:25, 31 October 2024
  • Thumbnail for Atopy
    treatment options with oral corticosteroids, biological treatments (e.g. omalizumab, mepolizumab) or allergen immunotherapy. Eczema Asthma Rhinitis Anaphylaxis...
    24 KB (2,561 words) - 17:54, 7 July 2024
  • mycophenolate, and azathioprine. Newer targeted medications, including omalizumab and belimumab, have also been used. Urticarial vasculitis is featured...
    6 KB (715 words) - 07:24, 4 August 2023
  • "Clot-busting" drug to treat acute myocardial infarction. 2003: Xolair (omalizumab): Subcutaneous injection for moderate to severe persistent asthma. 2003:...
    32 KB (2,865 words) - 04:21, 4 October 2024
  • Thumbnail for Eosinopenia
    of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for...
    14 KB (1,549 words) - 14:59, 25 October 2024
  • Thumbnail for Bi-specific T-cell engager
    et al. (2008). "Conversion of cetuximab, panitumumab, trastuzumab and omalizumab into T-cell-engaging BiTE antibodies creates novel drug candidates of...
    12 KB (1,727 words) - 23:52, 30 October 2024
  • Thumbnail for Aspergillus
     275–292. Zirbes JM, Milla CE (June 2008). "Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis". Pediatric...
    34 KB (3,380 words) - 03:33, 5 August 2024
  • biosimilar, in 2023. Products under development include biosimilars of omalizumab, denosumab, golimumab, aflibercept, vedolizumab, and pembrolizumab. In...
    11 KB (914 words) - 20:13, 22 June 2024
  • Thumbnail for Aspirin-exacerbated respiratory disease
    years have been used to treat AERD including dupilumab, mepolizumab, omalizumab, and benralizumab. Among treatment options, biologics have the highest...
    50 KB (5,530 words) - 02:09, 6 June 2024
  • asthma symptomatic control include omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab. Omalizumab binds to free human immunoglobulin...
    27 KB (2,765 words) - 09:13, 28 October 2024